Clinical Trial Detail

NCT ID NCT01788566
Title A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Gemcitabine + Necitumumab

Age Groups: adult

No variant requirements are available.